newsfilter
← Latest News
Business Wire·

Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM'21

An abstract showing tumor specific targeting at all known tumor sites in glioblastoma patients, with no normal tissue uptake of ifabotuzumab, from a Phase 1 study will be presented at EANM‘21 A Phase 1b study of ifabotuzumab in non-CNS solid tum